Please register here to attend this webinar or to receive the recording.

Dr. Dirk Mendel, Associate Director for Translational Science at SPARK at Stanford, will discuss how rethinking pharmacology studies can deliver more decision-ready data with less effort.

Background

There is a growing expectation that we generate more useful information from our animal pharmacology studies, and that these studies inform early clinical trial strategies so that teams can quickly reach Go/No Go decisions. However, despite this increased expectation, most groups continue to run the same studies they have run for decades. During this discussion, Dr. Mendel will make the case that there is a better way to approach in vitro and in vivo pharmacology studies to generate information better suited to the needs of the project and better positioned to improve decision-making as compounds progress into clinical development. The good news is that the proposed changes do not require working harder. Instead, they involve rethinking how studies are designed and how results are interpreted and reported. This approach is both more efficient and more effective, enabling teams to generate better and more useful data more quickly and with less work.

Dr. Dirk Mendel is a seasoned translational scientist and executive with over 30 years of experience in drug discovery and early clinical development across oncology, antivirals, and other therapeutic areas. He has contributed to the development of seven marketed drugs, including Sutent®, Tamiflu®, and Parsabiv®, through leadership roles in both biotech startups and major pharmaceutical companies. With deep expertise in PK/PD modeling, biomarker strategies, and portfolio management, he has driven programs from discovery through clinical proof-of-concept. Currently, he serves as Associate Director of Translational Science at Stanford’s SPARK program, advancing innovation in biomedicine.